CREB3 protein family: the promising therapeutic targets for cardiovascular and metabolic diseases.

IF 5.3 2区医学 Q2 CELL BIOLOGY

Cell Biology and Toxicology Pub Date : 2024-11-25 DOI:10.1007/s10565-024-09939-5

Yi-Peng Gao, Can Hu, Min Hu, Wen-Sheng Dong, Kang Li, Yun-Jia Ye, Yu-Xin Hu, Xin Zhang

引用次数: 0

Abstract

Significant advancements in cardiovascular and metabolic disease research have been made with the CREB3 protein family. Studies have revealed that members of this family are crucial in the development of these diseases, contributing to the regulation of lipid metabolism, inflammation, and vascular function. These studies provide useful information for future therapeutic strategies in cardiovascular and metabolic diseases.

查看原文本刊更多论文

CREB3 蛋白家族：心血管和代谢疾病的有望治疗靶点。

CREB3 蛋白家族在心血管和代谢疾病研究方面取得了重大进展。研究发现，该家族成员在这些疾病的发展过程中起着至关重要的作用，有助于调节脂质代谢、炎症和血管功能。这些研究为未来心血管和代谢疾病的治疗策略提供了有用的信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cell Biology and Toxicology 生物-毒理学

CiteScore

9.90

自引率

4.90%

发文量

101

审稿时长

>12 weeks

期刊介绍： Cell Biology and Toxicology (CBT) is an international journal focused on clinical and translational research with an emphasis on molecular and cell biology, genetic and epigenetic heterogeneity, drug discovery and development, and molecular pharmacology and toxicology. CBT has a disease-specific scope prioritizing publications on gene and protein-based regulation, intracellular signaling pathway dysfunction, cell type-specific function, and systems in biomedicine in drug discovery and development. CBT publishes original articles with outstanding, innovative and significant findings, important reviews on recent research advances and issues of high current interest, opinion articles of leading edge science, and rapid communication or reports, on molecular mechanisms and therapies in diseases.